1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124


Real-time Euronext Paris  -  05/27 11:35:12 am EDT
1.840 EUR   +2.22%
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
05/16Nicox Announces a New Governance Structure
05/16Nicox Announces a New Governance Structure
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development

12/13/2021 | 01:30am EDT
Press Release
Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development

December 13, 2021– release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the appointment of Doug Hubatsch to lead all of the Company’s non-clinical and clinical development activities. As Chief Scientific Officer, Doug Hubatsch will be responsible for setting the research and development strategy of the Group and will be a member of the Nicox Executive Committee, reporting to Michele Garufi, Chief Executive Officer. He will be based in Nicox’s US subsidiary Nicox Ophthalmics Inc., in Durham, North Carolina.

Doug will be responsible for implementing the future development strategy for all of our pipeline assets. He brings Nicox extensive experience in life sciences, focused on ophthalmology for the last 14 years, covering mid-late stage development, pre-marketing and commercial assets, specializing recently in glaucoma and ocular surface disease. He has successfully worked with the US FDA on a number of therapeutic products and his late-stage development and medical affairs expertise will be essential as Nicox prepares for the approval and potential launch of NCX 470. Overall, Doug’s broad scientific experience and multi-disciplinary background are an excellent fit for Nicox.” said Michele Garufi, Chairman and Chief Executive Officer of Nicox.

Doug Hubatsch joins Nicox from Novartis Pharmaceuticals, where he was Global Medical Head for Ocular Surface Disease and Digital Medicines within Global Medical Affairs. He has more than 25 years’ experience in Discovery Research, Development and Medical Affairs in Novartis, Alcon, Roche and AstraZeneca and has been involved with the launch of more than 10 products through his career including Simbrinza (Alcon) for glaucoma and Xiidra (Novartis) for dry eye disease.

The Nicox pipeline has great potential in two key areas that I have focused on recently – glaucoma and ocular surface disease, which includes blepharitis and dry eye.   I look forward to using my experience to benefit the development of Nicox’s pipeline, in strong collaboration with the existing experienced and international R&D team of the company. ” said Doug Hubatsch.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage

Bryan, Garnier & Co         Victor Floc’h        Paris, France
Cantor Fitzgerald        Louise Chen        New York, U.S.
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Damien Choplain        Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
LifeSci Advisors, LLC
Sophie Baumont
T +33 (0)6 27 74 74 49
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox’s website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99



  • EN_AppointmentDHubatsch PR_20211213_F

Primary Logo

Source: NICOX

2021 GlobeNewswire, Inc., source Press Releases

All news about NICOX SA.
05/16Ophthalmology Group Nicox Appoints New CEO, Chairman
05/16Nicox Announces a New Governance Structure
05/16Nicox Announces a New Governance Structure
05/16Nicox S.A. Announces Executive Changes
05/04NICOX : 2022 Ordinary Shareholder Meeting
05/04NICOX : 2022 Ordinary Shareholder Meeting
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
05/02NICOX AT ARVO 2022 : Presentation of clinical Phase 2 results on NCX 4251 and new non-clin..
04/28Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Pr..
04/11Nicox's NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma
More news
Sales 2022 9,03 M 9,67 M 9,67 M
Net income 2022 -20,3 M -21,8 M -21,8 M
Net cash 2022 2,49 M 2,67 M 2,67 M
P/E ratio 2022 -3,91x
Yield 2022 -
Capitalization 79,5 M 85,2 M 85,2 M
EV / Sales 2022 8,54x
EV / Sales 2023 6,85x
Nbr of Employees 33
Free-Float 89,6%
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,84 €
Average target price 11,50 €
Spread / Average Target 525%
EPS Revisions
Managers and Directors
Michele Garufi Chairman & Chief Executive Officer
Sandrine Gestin Vice President-Finance
José Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Jean-François Labbé Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-27.98%85
MERCK KGAA-21.50%83 006
KYOWA KIRIN CO. LTD.-12.92%11 543
INDIVIOR PLC25.37%2 855